Patent Assignment
Reel/Frame 029633/0837
Assignment of Assignor's Interest
Recorded: 2013-01-15
Pages: 8
Assignor
PROGENICS PHARMACEUTICALS, INC.
Executed: 2013-01-08
Assignee
CYTODYN, INC.
5 CENTERPOINTE DRIVE, SUITE 400, LAKE OSWEGO, OREGON, 97035
Covered Properties
(23)
Concentrated Protein Formulations and Uses Thereof
PCT:
PCT/US2011/026647 ↗
Method for Preventing Hiv-1 Infection of CD4+ Cells
Patent:
6,344,545 →
Application:
08/831,823 →
Fluorescence Resonance Energy Transfer Screening Assay for the Identification of Compounds Th at Are Capable of Abrogating Macrophage -Topic Hiv-1 Cell Fusion
Patent:
6,261,763 →
Application:
08/973,601 →
Monoclonal Antibodies and Method for Inhibiting Fusion of Hiv-1 to CD4+ Cells
Methods of Inhibiting Human Immunodeficiency Virus Type 1 (Hiv-1) Infection Through the Administration of CCR5 Chemokine Receptor Antagonists
Patent:
7,858,298 →
Application:
09/460,216 →
Methods for Inhibiting Hiv-1 Infection
Methods for Inhibiting Hiv-1 Envelope Glycoprotein-Mediated Membrane Fusion
Compositions and Methods for Inhibition of Hiv-1 Infection
Methods for Inhibiting Hiv-1 Infection
Anti-CCR5 Antibody
Methods for Assaying Inhibition of Hiv-1 Envelope Glycoprotein-Mediated Membrane Fusion
Methods of Inhibiting Human Immunodeficiency Virus Infection Through the Administration of Synergistic Combinations of Anti-CCR5 Monoclonal Antibodies, Fusion Inhibitors, and CD4-GP120 Binding Inhibitors.
Compounds Capable of Inhibiting Hiv-1 Infection
Anti-CCR5 Antibody
Anti-CCR5 Antibody
CCR5 Chemokine Receptor-Specific Monoclonal Antibodies Capable of Inhibiting Hiv-1 Cell Fusion
Methods of Inhibiting Infection by Diverse Subtypes of Drug-Resistant Hiv-1
Application:
12/452,739 →
Publication:
US 2011/0135634
Methods for reducing viral load in HIV-1 infected patients
Application:
12/590,005 →
Publication:
US 2010/0178290
Methods for Inhibiting Hiv-1 Replication Involving the Administration of an Anti-CCR5 Receptor Monoclonal Antibody and Small Molecule CCR5 Receptor Antagonist.
Method for Preventing Hiv-1 Infection of CD4+ Cells
Application:
13/093,331 →
Publication:
US 2013/0211043
Concentrated Protein Formulations and Uses Thereof
Methods for Reducing Viral Load in Hiv-1 Infected Patients
Concentrated protein formulations and uses thereof
Application:
61/339,191 →
Related Assignments
(11)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jan 11, 2002
From: OLSON, WILLIAM C.; MADDON, PAUL J.
To: PROGENICS PHARMACEUTICALS, INC.
Reel/Frame 012455/0713 →
Assignment of Assignor's Interest
Aug 18, 2003
From: TSURUSHITA, NAOYA; HINTON, PAUL R.; VASQUEZ, MAXIMILLANO
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 014392/0780 →
Assignment of Assignor's Interest
Aug 18, 2003
From: OLSON, WILLIAM C.; MADDON, PAUL J.
To: PROGENICS PHARMACEUTICALS, INC.
Reel/Frame 014393/0471 →
Change of Name
May 22, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017655/0436 →
Assignment of Assignor's Interest
Mar 4, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 022343/0275 →
Assignment of Assignor's Interest
Feb 13, 2010
From: OLSON, WILLIAM C.
To: PROGENICS PHARMACEUTICALS, INC.
Reel/Frame 023947/0491 →
Assignment of Assignor's Interest
Jun 25, 2010
From: OLSON, WILLIAM C.; MADDON, PAUL J.; ISRAEL, ROBERT J.; PEVEAR, DANIEL C.
To: PROGENICS PHARMACEUTICALS, INC.
Reel/Frame 024598/0994 →
Change of Name
Dec 7, 2010
From: FACET BIOTECH CORPORATION
To: ABBOTT BIOTHERAPEUTICS CORP.
Reel/Frame 025445/0807 →
Assignment of Assignor's Interest
Mar 30, 2011
From: CHEN, TRACY T.
To: PROGENICS PHARMACEUTICALS, INC.
Reel/Frame 026049/0226 →
Assignment of Assignor's Interest
Sep 27, 2011
From: OLSON, WILLIAM C.; MADDON, PAUL J.; PEVEAR, DANIEL C.; ISRAEL, ROBERT J.
To: PROGENICS PHARMACEUTICALS, INC.
Reel/Frame 026975/0384 →
Change of Name
Feb 19, 2013
From: ABBOTT BIOTHERAPEUTICS CORP
To: ABBVIE BIOTHERAPEUTICS INC.
Reel/Frame 029834/0215 →